Table 4.
Results of switching from ranibizumab to aflibercept
| Study | Sample size (eyes) | Reason for switch | FU duration | Outcome (mean change) | |
|---|---|---|---|---|---|
| Gharbiya et al. [36] | 31 | Persistent intraretinal or subretinal fluid with or without PED following RBZ treatments | 6 months | VA | No change (0.3 letters) |
| CSF | Decreased* (−180 μm) | ||||
| Heussen et al. [37] | 12 | Diminishing effect over time or persistent intra- or subretinal fluid following RBZ treatments | 4 injections after the switch | VA | Improved (−0.22 logMAR) |
| CSF | Decreased* (−67 μm) | ||||
| Kumar et al. [38] | 34 | Persistent subretinal and/or intraretinal fluid despite previous RBZ treatments | 6 months | VA | Improved* (−0.1 logMAR) |
| CFT | Decreased* (−168 μm) | ||||
| Kawashima et al. [39] | 15 | Recurrent or residual exudative changes after the last three RBZ injections | 6 months | VA | No change (0.01 logMAR) |
| CRT | Decreased* (−71 μm) | ||||
| Batioglu et al. [40] | 29 | Persistent intraretinal or subretinal fluid and PED following RBZ treatments | 4.55 ± 2.14 months | VA | No change (−0.06 logMAR) |
| CMT | Decreased* (−126 μm) | ||||
| Gerding et al. [41] | 40 | Persistent or recurrent intra- and/or subretinal fluid | 6 months | VA | Improved* (0.65 ETDRS lines) |
| CFT | Decreased* (−96 μm) | ||||
* p value ≤ 0.05